Publications & Posters
pan-LOX Inhibitors |
||
Title: Topical application of an irreversible small molecule inhibitor of lysyl oxidases ameliorates skin scarring and fibrosis Authors: Chaudhari, N., Findlay, AD., Stevenson, AW., Clemons, TD., Yao, Y., Joshi, A., Sayar, S., Wallace, G., Rea, S., Toshniwal, P., Deng, Z., Melton, PE., Hortin, N., Iyer, KS., Jarolimek, W., Wood, FM., Fear, MW. Reference: Nature Communications 2022, doi.org/10.1038/s41467-022-33148-5 |
||
Title: Novel lysyl oxidase inhibitors attenuate hallmarks of primary myelofibrosis in mice Authors: Leiva, O., Ng, S. K., Matsuura, S., Chitalia, V., Lucero, H., Findlay, A., Turner, C., Jarolimek, W. and Ravid, K. Reference: International Journal of Hematology 2019, 110(6), 699. doi.org/10.1007/s12185-019-02751-6 |
||
Title: Pan-Lysyl Oxidase Inhibitor PXS-5505 Ameliorates Multiple-Organ Fibrosis by Inhibiting Collagen Crosslinks in Rodent Models of Systemic Sclerosis Authors: Yao, Y., Findlay, A., Stolp, J., Rayner, B., Ask, K. and Jarolimek, W. Reference: International Journal of Molecular Sciences 2022 May 16; 23(10), 5533. doi.org/10.3390/ijms23105533 |
||
Title: Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer
Authors: Chang, J., Lucas, M. C., Leonte, L. E., Garcia-Montolio, M., Singh, L. B., Findlay, A. D., Deodhar, M., Foot, J. S., Jarolimek, W., Timpson, P., Erler, J. T. and Cox, T. R. Reference: Oncotarget. 2017 Apr 18;8(16):26066-26078. doi: 10.18632/oncotarget.15257 |
||
Title: A Novel Lysyl Oxidase Inhibitor Attenuates Bone Marrow Fibrosis and Decreases Spleen Size in a Mouse Model of Primary Myelofibrosis Authors: Leiva, O., Matsuura, S., Findlay,A., Turner, C., Jarolimek, W. and Ravid, K. Reference: Blood 2017 130:4214; |
||
SSAO Inhibitors |
||
Title: Semicarbazide sensitive amine oxidase and vascular adhesion protein-1: one protein being validated as a therapeutic target for inflammatory diseases Authors: McDonald, I. A., Foot, J., Yin, P., Flening, E. and van Dam, E. M. Reference: Annual Reports in Medicinal Chemistry 2007, 42, 229. doi.org/10.1016/S0065-7743(07)42015-2 |
||
Title: Combining monoamine oxidase B and semicarbazide-sensitive amine oxidase enzyme inhibition to address inflammatory disease Authors: Foot, J. S., Buson, A., Deodhar, M., Findlay, A. D., Robertson, A. D., Turner, C. I., Yow, T., Zhou, W. and Jarolimek, W. Reference: Bioorg Med Chem Lett. 2022, 74: 128942. doi.org/10.1016/j.bmcl.2022.128942. Epub 2022 Aug 11. |
||
Title: Inhibition of vascular adhesion protein 1 protects dopamine neurons from the effects of acute inflammation and restores habit learning in the striatum. Authors: Becchi, S., Buson, A. & Balleine, B.W. Reference: J Neuroinflammation 18, 233 (2021). https://doi.org/10.1186/s12974-021-02288-8Link: https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-021-02288-8 |
||
Title: Semicarbazide-Sensitive Amine Oxidase Inhibition Ameliorates Albuminuria and Glomerulosclerosis but Does Not Improve Tubulointerstitial Fibrosis in Diabetic Nephropathy Authors: Wong, M. Y., S. Saad, M. G. Wong, S. Stangenberg, W. Jarolimek, H. Schilter, A. Zaky, A. Gill, and C. Pollock Reference: PLoS One 15, no. 6 (2020): e0234617. |
||
Title: Inhibition of semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 reduces lipopolysaccharide-induced neuroinflammation Authors: Becchi, S., Buson, A., Foot, J., Jarolimek, W. and Balleine, B. W. Reference: Br J Pharmacol. 2017 Jul;174(14):2302-2317. doi: 10.1111/bph.13832. Epub 2017 Jun 10. |
||
Title: The inhibitor of semicarbazide-sensitive amine oxidase, PXS-4728A, ameliorates key features of chronic obstructive pulmonary disease in a mouse model Authors: Jarnicki, A. G., Schilter, H., Liu, G., Wheeldon, K., Essilfie, A. T., Foot, J. S., Yow, T. T., Jarolimek, W. and Hansbro, P. M. Reference: Br J Pharmacol. 2016 Nov;173(22):3161-3175. doi: 10.1111/bph.13573. Epub 2016 Oct 12. |
||
Title: Effects of an anti-inflammatory VAP-1/SSAO inhibitor, PXS-4728A, on pulmonary neutrophil migration Authors: Schilter, H. C., Collison, A., Russo, R. C., Foot, J. S., Yow, T. T., Vieira, A. T., Tavares, L. D., Mattes, J., Teixeira, M. M. and Jarolimek, W. Reference: Respir Res. 2015 Mar 20;16:42. doi: 10.1186/s12931-015-0200-z. |
||
Title: Semicarbazide-sensitive amine oxidase (SSAO) inhibition ameliorates kidney fibrosis in a unilateral ureteral obstruction murine model Authors: Wong, M., Saad, S., Zhang, J., Gross, S., Jarolimek, W., Schilter, H., Chen, J. A., Gill, A. J., Pollock, C. A. and Wong, M. G. Reference: Am J Physiol Renal Physiol. 2014 Oct 15;307(8):F908-16. doi: 10.1152/ajprenal.00698.2013. Epub 2014 Aug 20. |
||
Title: PXS-4681A, a potent and selective mechanism-based inhibitor of SSAO/VAP-1 with anti-inflammatory effects in vivo Authors: Foot, J. S., Yow, T. T., Schilter, H., Buson, A., Deodhar, M., Findlay, A. D., Guo, L., McDonald, I. A., Turner, C. I., Zhou, W. and Jarolimek, W. Reference: J Pharmacol Exp Ther. 2013 Nov;347(2):365-74. doi: 10.1124/jpet.113.207613. Epub 2013 Aug 13. |
||
Title: The discovery and development of selective 3-fluoro-4-aryloxyallylamine inhibitors of the amine oxidase activity of semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 (SSAO/VAP-1) Authors: Foot, J. S., Deodhar, M., Turner, C. I., Yin, P., van Dam, E. M., Silva, D. G., Olivieri, A., Holt, A. and McDonald, I. A. Reference: Bioorg Med Chem Lett. 2012 Jun 15;22(12):3935-40. doi: 10.1016/j.bmcl.2012.04.111. Epub 2012 Apr 30. |
||
LOXL2 Inhibitors |
||
Title: An activity-based bioprobe differentiates a novel small molecule inhibitor from a LOXL2 antibody and provides renewed promise for anti-fibrotic therapeutic strategies
Authors: Findlay, A., Turner, C., Schilter, H., Deodhar, M., Zhou, W., Perryman, L., Foot, J., Zahoor, A., Yao, Y., Hamilton, R., Brock, M., Raso, C., Stolp, J., Galati, M., Hamprecht, D., Charlton, B. and Jarolimek, W. Reference: Clinical and Translational Medicine 2021) 11(11), e572. doi.org/10.1002/ctm2.572 |
||
Title: Inhibition of LOXL2 and other lysyl oxidase (like) enzymes: intervention at the core of fibrotic pathology
Authors: Findlay, A., Turner, C. and Hamprecht, D. Reference: RSC Drug Discovery Series 2020, 73, 145. doi.org/10.1039/9781788015783-00145 |
||
Title: Lysyl oxidase inhibitors attenuate cyclosporin A-induced nephropathy in mouse Authors: Nguyen LT, Saad S, Shi Y, Wang R, Chou ASY, Gill A, Yao Y, Jarolimek W, Pollock CA Reference:. Sci Rep (2021) 11, 12437 doi.org/10.1038/s41598-021-91772-5 |
||
Title: The lysyl oxidase like 2/3 enzymatic inhibitor, PXS‐5153A, reduces crosslinks and ameliorates fibrosis Authors: Heidi Schilter, Alison D. Findlay, Lara Perryman, Tin T. Yow, Joshua Moses, Amna Zahoor, Craig I. Turner, Mandar Deodhar, Jonathan S. Foot, Wenbin Zhou, Angelique Greco, Amar Joshi, Benjamin Rayner, Sarah Townsend, Alberto Buson, Wolfgang Jarolimek. Reference: J Cell Mol Med. 2018;1–12. |
||
Title: Nanoscale dysregulation of collagen structure-function disrupts mechano-homeostasis and mediates pulmonary fibrosis Authors: M.G. Jones, O.G. Andriotis, J.J.W. Roberts, K. Lunn, V.J. Tear, L. Cao, K. Ask, D.E. Smart, A. Bonfanti, P. Johnson, A. Alzetani, F. Conforti, R. Doherty, C.Y. Lai, B. Johnson, K.N. Bourdakos, S.V. Fletcher, B.G. Marshall, S. Joga9, C. Brereton, S.J. Chee, C. Ottensmeier, P. Sime, J. Gauldie, M. Kolb, S. Mahajan, A. Fabre, A. Bhaskar, W. Jarolimek, L. Richeldi, K.M.A. O’Reilly, P.D. Monk, P.J. Thurner, D.E. Davies Reference: eLife |
||
Title: Identification and Optimization of Mechanism-Based Fluoroallylamine Inhibitors of Lysyl Oxidase-Like 2/3. Authors: Findlay, A. D., J. S. Foot, A. Buson, M. Deodhar, A. G. Jarnicki, P. M. Hansbro, G. Liu, et al. Reference: J Med Chem 62, no. 21 (Nov 14 2019): 9874-89.Link: https://doi.org/10.1021/acs.jmedchem.9b01283 |
||
Title: Lysyl oxidase-like 2 inhibition ameliorates glomerulosclerosis and albuminuria in diabetic nephropathy Authors: Stangenberg, S., Saad, S., Schilter, H., Zaky, A., Gill,A. Pollock, C., and Wong, M.G. Reference Sci Rep 8, no. 1 (Jun 21 2018): 9423.Link: https://doi.org/10.1038/s41598-018-27462-6Reference: Scientific reports in press |
||
Title: Multiple Functions of Lysyl Oxidase Like-2 in Oral Fibroproliferative Processes Authors: Saxena, D., Mahjour, F., Findlay, A. D., Mously, E. A., Kantarci, A. and Trackman, P. C. Reference: J Dent Res. 2018 May 1:22034518775971. doi: 10.1177/0022034518775971. |
||
Title: Inhibition Of LOXL2: Pharmaxis' Small Molecule Approach To Treat Fibrosis Authors: Buson, A., Cock, T.A., Deodhar, M., Findlay, A.D., Foot, J. S., Jarnicki, A., Moses, J., Turner, C. I., Yow, T. T., Zhou, W., Hansbro, P. M. and Jarolimek, W. Reference: DOI: 10.1164/ajrccm-conference.2014.189.1_MeetingAbstracts.A6669 |
||
Title: Inhibition of Collagen cross-links by novel LOXL2 selective inhibitors in an in-vitro model of fibroblastic foci of IPF Authors: Roberts J., Lunn K., Tear V., Jones M., Davies D., Jarolimek W., Cao L., Montfort T., Mahajan S., Andriotis O., Thurner P., Monk P. Link: read poster from ERS 2016 |
||
Title: Inhibition of Lysyl Oxidase Like-2 (LOXL2) reduces cardiac interstitial fibrosis in mice Authors: Buson A., Cao L., Deodhar M., Findlay A.D., Foot J.S., Greco A., Jarolimek W., Moses J., Perryman L., Rayner B., Schilter H.C., Tan X., Turner., Yow T.T., Zahoor A., Zhou W. Link: read poster |
||
Title: Inhibition of Lysyl Oxidase Like-2 reduces accumulation and collagen cross-links in CCL4-induced liver fibrosis Authors: Jarolimek W., Buson A., Cao L., Deodhar M., Findlay A.D., Foot J.S., Greco A., Moses J., Schilter H.C., Tan X., Turner., Yow T.T., Zhou W. Link: read poster |
||
Other |
||
Title: Measurement of collagen cross-links from tissue samples by mass spectrometry
Authors: Joshi, A., Zahoor, A. and Buson, A. Reference: Methods in Molecular Biology (New York, NY, United States) 2019, 1944, 79. doi.org/10.1007/978-1-4939-9095-5_6 |
||
Title: Synthetic Studies on the Natural Product Myrsinoic Acid F Reveal Biologically Active Analogues Authors: Mikusek, J., Nugent, J., Ward, J. S., Schwartz, B. D., Findlay, A. D., Foot, J. S. and Banwell, M. G. Reference: Org Lett. 2018 Jun 11. doi: 10.1021/acs.orglett.8b01558. |
||
Title: The effect of non-specific tight junction modulators on the transepithelial transport of poorly permeable drugs across airway epithelial cells Authors: Ghadiri, M., Young, P. M., Jarolimek, W., Grau, G. E., Oliver, B. G. and Traini, D. Reference: J Drug Target. 2017 Apr;25(4):342-349. doi: 10.1080/1061186X.2016.1258703. Epub 2016 Nov 24. |
||
Title: Effect of polyunsaturated fatty acids (PUFAs) on airway epithelial cells' tight junction Authors: Ghadiri, M., Mamlouk, M., Spicer, P., Jarolimek, W., Grau, G. E., Young, P. M. and Traini, D. Reference: Pulm Pharmacol Ther. 2016 Oct;40:30-8. doi: 10.1016/j.pupt.2016.07.004. Epub 2016 Jul 22. |
||
Title: The mannose-6-phosphate analogue, PXS64, inhibits fibrosis via TGF-beta1 pathway in human lung fibroblasts Authors: Schilter, H., Cantemir-Stone, C. Z., Leksa, V., Ohradanova-Repic, A., Findlay, A. D., Deodhar, M., Stockinger, H., Song, X., Molloy, M., Marsh, C. B. and Jarolimek, W. Reference: Immunol Lett. 2015 Jun;165(2):90-101. doi: 10.1016/j.imlet.2015.04.003. Epub 2015 Apr 27. |
||
Title: Mannitol enhances antibiotic sensitivity of persister bacteria in Pseudomonas aeruginosa biofilms Authors: Barraud, N., Buson, A., Jarolimek, W. and Rice, S. A. Reference: PLoS One. 2013 Dec 13;8(12):e84220. doi: 10.1371/journal.pone.0084220. eCollection 2013. |